Professor Thomas Powles discusses the EV 301 trial and what these results mean for patients with metastatic urothelial carcinoma

Professors Dean Fennell and Garteh Griffiths, co-lead investigators of the phase III CONFIRM trial, share the results of the study of nivolumab and discuss what these results mean for patients with relapsed mesothelioma.

Dr. Sabari shares the results of a phase I study of amivantamab and discusses what these results means for patients with metastatic non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations. 

Prof. dr. Michael Boyer shares the results of the phase II CodeBreak 100 trial and discusses what these results mean for patients with non-small cell lung cancer harbouring G12C KRAS mutations

In this podcast, Professor Michael Boyer discusses the Keynote 598 trial and what these results mean for the future of dual immunotherapy combinations. 

In this podcast prof. dr. Sylvie Rottey (UZ Ghent) discusses the updated BSMO guidelines for the treatment of patients with advanced adrenal cell carcinoma.

Jia Ruan, MD, PhD from the Weill Cornell Medical College in New York (USA), discusses a Phase II study aiming to evaluate the efficacy and safety of combined azacitidine and CHOP as initial treatment in peripheral T-cell lymphoma (PTCL) patients. 

Prof. dr. Jean-Luc Van Laethem shares the results of the second cohort from the KEYNOTE 224 study, and what these results mean moving forward.

Prof. Dr. Eric Van Cutsem shares the results of the phase II TASCO1 trial and discusses what these findings mean moving forward.